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Abbreviation 
 
AB antibody 
ATP Adenosintriphosphate  
bp  base pair 
BSA  bovine serum albumin 
cDNA  complementary deoxyribonucleic acid 
cm  centimeter 
CRE  cyclization recombination 
DNA  deoxyribonucleic acid 
dNTP  deoxynucleotide triphosphates 
E. coli  Escherichia coli 
ES  cells embryonic stem cells 
FCS  fetal calf serum 
g  gram 
GAPDH Glycerinaldehyd-3-phosphat-dehydrogenase 
GFP  green fluorescent protein 
GITC  guanidinium isothiocyanate  
h  hour 
IL-1 interleukine- 1  
HRP  horseradish peroxidase 
kD  kilo dalton 
kb  kilo base 
l  liter 
LB  Luria Broth 
  2 
M  molar 
mA  milliampere 
mg  milligram 
min  minute 
ml  millimeter 
mM  millimolar 
mRNA  messenger ribonucleic acid 
nm  nanometer 
ng  nanogram 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
pg  picogram 
psi pound per square inch 
PVDF Polyvinylidenfluorid 
RNA  ribonucleic acid 
RNAi ribonucleic acid interference  
ROS  reactive oxygen species 
rpm  revolution per minute 
RPMI 1640 Roswell Park Memorial Institute medium 
RT  room temperature 
RT-PCR  reverse transcription polymerase chain reaction 
s  second 
SDS  sodium dodecyl sulphate 
siRNA small interfering ribonucleic acid 
TBS  Tris-buffered saline 
  3 
TBE  Tris- Boric acid- EDTA 
UV  ultraviolet 
µg  microgram 
µl  microliter 
µm  micrometer 
WT  wild-type 
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I. Introduction 
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Apoptosis (= programmed cell death) is a key regulator of tissue homeostasis. An imbalance 
between cell death and proliferation may result in tumour formation. Also, killing of cancer 
cells by cytotoxic therapies such as chemotherapy, γ-irradiation or ligation of death receptors 
is predominantly mediated by triggering apoptosis in target cells. In addition to the intrinsic 
apoptotic pathway, elements of death receptor signaling pathways have been identified to 
contribute to the efficacy of cancer therapy. Failure to undergo apoptosis in response to 
anticancer therapy may lead to resistance. Also, deregulated expression of death receptor 
pathway molecules may contribute to tumourgenesis and tumour escape from endogenous 
growth control. Understanding the molecular events that regulate apoptosis provides new 
opportunities for pathway- based rational therapy. 
 
1. Apoptosis and Necrosis 
 
Naturally occurring cell death is an inconspicuous, yet prevalent, event in complex 
multicellular organism, and was first described by anatomists and embryologists in the 19th 
century [Fadeel and Orrenius, 2005;Clarke and Clarke, 1996;Lockshin and Zakeri, 2001]. 
However, interest in the subject was modest, and the concept of physiological cell death did 
not receive widespread recognition until the publication of a seminal paper on apoptosis by 
Kerr and colleagues some 30 years ago [Kerr et al., 1972]. These authors highlighted the 
significance of controlled cell deletion and described the morphological features of this active 
and inherently programmed phenomenon, which they proposed plays a “complementary but 
opposite role to mitosis in the regulation of animal cell populations”. The importance of their 
study lies not only in the detailed morphological description of apoptosis (a term derived from 
the Greek word describing the falling off leaves from a tree) but also in the recognition  of 
natural cell death as a basic phenomenon not restricted to embryogenesis [Wyllie et al., 1980]. 
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Figure 1: Diagramatic comparison of necrotic cells 
Adapted from http://www.intl.elsevierhealth.com/e-
books/pdf/852.pdf 
 
Cell death is therefore an essential strategy for the control of the dynamic balance in living 
systems and two fundamentally different forms of cell death, apoptosis and necrosis, have 
been defined since.  
Necrosis is an accidental passive process starting with disruption of the cell membrane and a 
progressive breakdown of ordered cell structures in response to violent environmental 
perturbations such as severe hypoxia/ ischaemia, extremes of temperature and mechanical 
trauma. Under physiological conditions direct damage to the plasma membrane is evoked by 
agents like complement and lytic viruses. 
Necrosis begins with an impairment of the cell’s ability to maintain homeostasis, leading to an 
influx of water and extracellular ions. Intracellular organelles, most notably the mitochondria, 
and the entire cell swell and rupture (cell lysis). Due to the ultimate breakdown of the plasma 
membrane, the cytoplasmic contents including lysosomal enzymes are released into the 
extracellular fluid. Therefore, in vivo, necrotic cell death is often associated with extensive 
tissue damage resulting in an intense inflammatory response (see Figure 1).  
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Figure 2: Diagramatic comparison of apoptotic 
cells 
Adapted from http://www.intl.elsevierhealth.com/e-
books/pdf/852.pdf 
 
In contrast, apoptosis or programmed cell death involves the activation of an energy-requiring 
intracellular machinery, which is tightly regulated and conserved throughout evolution [Yuan, 
1996]. Apoptosis is defined on the basis of morphological changes including chromatin 
condensation, nuclear fragmentation and formation of apoptotic bodies containing intact 
organelles, as well as portions of the nucleus (see Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The apoptotic bodies are enclosed by an intact plasma membrane and rapidly recognized, 
ingested and degraded by phagocytes or neighbouring cells. As apoptosis typically does not 
induce inflammation or tissue scarring, it is well suited for a role in normal cell turnover 
during embryogenesis and in adult tissues [Jacobson et al., 1997]. 
Apoptosis and necrosis are usually considered separate entities, but an alternate view is 
emerging that apoptosis and necrosis are frequently the consequence of the same initiating 
factors and signalling pathways. Rather than being separate entities, apoptosis and necrosis in 
their pure form may represent extremes on a continuum of cell death [Lemasters, 
1999;Lemasters, 2005].  
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2. Molecular mechanism of apoptosis 
 
Most of the morphological changes that were observed by Kerr et al. [Kerr et al., 1972] are 
caused by a set of cysteine proteases that are activated specifically in apoptotic cells. These 
death proteases are homologous to each other, and are part of a large protein family known as 
the caspases [Alnemri et al., 1996]. Caspases are highly conserved through evolution, and can 
be found from humans all the way down to insects, nematodes and hydra [Budihardjo et al., 
1999;Cikala et al., 1999;Earnshaw et al., 1999]. Over the past decade, many key events in 
caspase regulation have been documented at the molecular and cellular level [Danial and 
Korsmeyer, 2004]. 
Two main pathways that activate caspases have been identified. The first (“extrinsic pathway) 
begins at the cell surface and involves ligand-induced activation of death receptors, such as 
TNFRI and CD95, which then recruit and activate caspases. The second (“intrinsic pathway”) 
involves mitochondrial integration of cellular stress signals and subsequent release into the 
cytosol of cytochrome c, which activates caspases via the adapter molecule “apoptotic 
protease activating factor-1” (APAF-1). 
 
2.1. Receptor mediated apoptosis (Extrinsic pathway) 
 
The extrinsic apoptosis pathway follows the activation of specific membrane receptors, the 
death receptors. Although death receptors can promote cell growth under at least some 
situations [Algeciras-Schimnich et al., 2002], the ability of these receptors to induce apoptosis 
is critical in several disease processes and has been the focus of most work today. 
Death receptors are members of the TNF receptor gene superfamily, which consists of more 
than 20 proteins with a broad range of biological functions including the regulation of cell 
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death and survival, differentiation or immune regulation [Ashkenazi and Dixit, 
1998;Krammer, 2000;Walczak and Krammer, 2000] (see Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The TNF- and TNF- receptor superfamily. Bottom line Receptors, upper line Ligands. Pink oblong 
Death domain (DD). Taken from http://www.dkfz-heidelberg.de/immungenetik/apoptosis-cd95.htm.  
 
The best-characterized death receptors comprise CD95 (APO-1/Fas), the TNF- receptor 1 
(TNFR1) and the related TRAIL-R1 and TRAIL-R2 (TNF- related apoptosis-inducing ligand 
receptors).  
 
2.1.1 CD95 (APO-1/Fas)/CD95L (FasL) 
 
CD95 (APO-1/Fas) first appeared in the literature in 1989, when it was described by two 
independent groups led by Minako Yonehara in Japan [Yonehara et al., 1989] and Peter 
Krammer in Germany [Trauth et al., 1989]. CD95 is a glycosylated cell-surface protein, 
ubiquitously expressed in various tissues, in particular in thymus, liver, heart, kidney and in 
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inactivated mature lymphocytes. In order to avoid unnecessary activation of the apoptotic 
pathway, CD95 expression and localization are tightly regulated. Only a minimal amount of 
CD95 is expressed on the plasma membrane in unstimulated cells, whereas the majority  of 
the receptor is localized in the cytosol, in particular, in the Golgi complex and the trans-Golgi 
network [Sodeman et al., 2000;Bennett et al., 1998]. After a proapoptotic stimulus, CD95 
containing vesicles translocate to the cell surface, increasing CD95 expression on the plasma 
membrane and initiating the apoptotic signal [Sodeman et al., 2000]. Engagement of CD95 by 
either agonistic antibodies or CD95L (FasL) leads to the trimerisation of the receptor, 
followed by recruitment of the adaptor protein FADD (Fas Associated Death Domain)/ 
MORT-1 (mediator of receptor induced toxicity) [Wallach et al., 1999] (see section 2.2 in 
introduction). FADD associates with its receptor through intersection of its death domains, 
while its death effector domain binds to a correspondent death effector domain (DED) or a 
caspase recruitment domain (CARD) in the prodomain of inactive initiator caspase, such as 
procaspase-8 and -10. The resulting complex is called the death –inducing signaling complex 
(DISC) [Peter and Krammer, 2003;Kischkel et al., 1995] (Figure 4). 
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Recruitment and accumulation of procaspase-8/-10 at the DISC result in self processing and 
spontaneous activation of the caspase via autoproteolytic cleavage. Active caspase-8 (FLICE) 
is released from the DISC into the cytoplasm and cleaves various proteins in the cell such as 
caspase-3, -6 and -7, which are ultimately responsible for the degradation of key cellular 
components resulting of the completion of the cell death programme. 
Additional DED-containing proteins have been found in a certain class of herpes viruses. 
These proteins are called FLIP and bind to the CD95-FADD complex. It exists in a short 
Figure 4: The CD95/Fas death inducing signaling complex. 
Schematic representation of the DISC formed after the engagement of CD95L/FasL to CD95/Fas. The DD on 
the adapter protein FADD interacts with the receptor´s DD, whereas the DED binds the correspondent death 
effector domain in the pro-domain of the inactive initator caspase-8/-10. The short form of the inhibitor of 
apoptosis cFLIP (cFLIPs) binds to the DED of FADD and prevents the recruitment of the initator pro-caspases 
to the DISC, whereas the ling form of the cFLIP (cFLIPL) allows the recruitment of the procaspase-8 to the 
DISC, but inhibits its processing into the active form. 
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(cFLIPS) and a long isoform (cFLIPL), as a result of different splice variants. Both forms of 
cFLIP are recruited and bind to the DISC upon stimulation [Scaffidi et al., 1999] and inhibit 
procaspase-8 recruitment to the DISC (Figure 4). 
 
2.1.2 TRAIL (Apo2L) and its receptor 
 
TRAIL/Apo2L (Apo 2 Ligand or tumour necrosis factor related apoptosis inducing ligand) 
was discovered by two independent groups, based on its sequence homology to TNF and 
CD95L [Pitti et al., 1996;Wiley et al., 1995]. Like most other members of the TNF 
superfamily of ligands, TRAIL/Apo2L is primarily expressed as a type II membrane protein 
of about 33-35 kDa [Liabakk et al., 2002] and is capable to induce apoptosis [Walczak and 
Krammer, 2000].  
The receptor system for TRAIL/Apo2L is complex and comprises four exclusive receptors. 
Two of these- DR4 (TRAIL-receptor-1 (TRAIL-R1)) and DR5 (TRAIL-receptor-2 (TRAIL-
R2), KILLER, TRICK2) - are death receptors which contain a cytoplasmic death domain that 
is able to transduce an apoptotic signal. By contrast, two other receptors DcR1 (TRAIL-
receptor-3, (TRAIL-R3), TRIDD, LIT) and DcR2 (TRAIL-receptor-4 (TRAIL-R4), 
TRUNDD) are unable to initiate apoptotic cell death and believed to act as decoys. Finally, a 
soluble receptor called osteoprotegerin (OPG) also exists that binds with low affinity to 
TRAIL at physiological temperatures [Truneh et al., 2000].  
In particular, CD95 and TRAIL share a similar pattern of intracellular signal transduction: 
binding of TRAIL to TRAIL-R1 and/or TRAIL-R2 results in recruitment of the adaptor 
protein FADD. FADD recruits procaspase-8 via its death effector domain (DED) to form the 
membrane protein complex DISC [Sprick et al., 2000]. In turn, active caspase-8 cleaves 
downstream caspases as the effector caspase 3, leading to cleavage of cellular proteins, DNA 
and subsequent programmed cell death [Salvesen and Abrams, 2004;Earnshaw et al., 1999]. 
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2.1.3. Tumour necrosis factor pathway 
 
TNF (tumour necrosis factor) binds to two different receptors, TNF receptor 1 and 2 (TNF-
R1/TNF-R2). TNF-R1 assembles a DISC similar to CD95, TRAIL-R1 and TRAIL-R2 with 
TRADD (tumour necrosis factor receptor 1 associated death domain protein) as additional 
adapter for the FADD/ procaspase-8 complex [Chen and Goeddel, 2002]. 
In contrast to other death receptors, TNF-R1 has pleiotropic activities such as induction of 
apoptosis and activation of the transcription factor NF-κB, leading to the induction of a 
number of antiapoptotic proteins. Activation of the NF-κB axis proceeds via a multi protein 
complex containing TRADD, RIP1, TRAF2 and cIAP1, binding to TNF-R1 (complex 1). 
Upon biochemical modifications in RIP1, TRAF2 and TRADD, complex 1 dissociates from 
TNF-R1 and a complex consisting of FADD, procaspase 8, cFLIP and procaspase-10 binds to 
the receptor (complex 2). Thus, antiapoptotic and apoptotic pathways are subsequently 
activated from the same receptor [Micheau and Tschopp, 2003] (Figure 5). 
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2.2. Mitochondrial mediated apoptosis (intrinsic pathway) 
 
In contrast to the extrinsic apoptosis pathway, the intrinsic pathway is stimulated from inside 
the cell. Various stimuli (e.g., UV- irradiation, reactive oxygen species [ROS], growth factor 
withdrawal or chemotherapeutic drugs) activate mitochondria through Bcl-2 family members- 
Bax and Bak. From mitochondria, caspase-dependent or –independent apoptosis signalling 
pathways are initiated. Participation of mitochondria in apoptosis induction mainly involves 
Figure 5: Model of TNFR1- Mediated Apoptosis.  
After binding of TNF to TNFR1, rapid recruitment of TRADD, RIP1, and TRAF2 occurs (complex I). 
Subsequently TNFR1, TRADD, and RIP1 become modified and dissociate from TNFR1. The liberated death 
domain of TRADD (and/ or RIP1) now binds to FADD, resulting in caspase 8/10 recruitment (forming complex 
II) and resulting in apoptosis. If NF-κB activation triggered by complex I is successful, cellular FLIP L levels are 
sufficiently elevated to block apoptosis and cell survive.  
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the release of caspase activating proteins into the cytosol. The release of cytochrome c from 
the mitochondria results in the activation of the apoptotic protease activating factor-1 (Apaf-
1). In the presence of cytochrome c and ATP, the CARD domain of Apaf-1 binds with the 
CARD domain of procaspase 9, and this forms the mitochondrial DISC, also designated as 
apoptosome [Zou et al., 1997]. Following activation, the apoptosome-associated caspase-9 
will in turn activate downstream caspases like caspase 3, 6 and 7 [Li et al., 1997]. 
Common to all these events is that they lead to efflux of cytochrome c, usually located in the 
lumen between the inner and outer membrane from the mitochondria. Key to regulating the 
integrity of the mitochondrial membrane is proteins of the Bcl-2 family which can be divided 
into three subfamilies according to the presence of the Bcl-2 homology domains (BH): BH3-
only, BH1-BH4 and BH1-BH3 family members. Bcl-2, Bcl-xL, Mcl-1, A1, Boo/Diva and 
Bcl-w belongs to the second subgroup and act as antiapoptotic proteins. The third subgroup 
includes Bax, Bak and, Bok and the proteins Bad, Bid, Bim, Bod, Bik, Puma and Noxa which 
act proapoptotically belongs to the BH-3 only proteins. 
 (see Figure 6). 
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Figure 6: The major apoptotic pathways in mammalian cells  
(Adapted from: Hengartner, MO. The biochemistry of apoptosis. Nature 2000; 407:770- 776) 
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2.3. Caspases 
 
Caspases are aspartic acid-specific cysteine proteases, which become activated in most forms 
of apoptosis. In cells, they localise in nucleus, cytoplasm and mitochondrial intermembrane 
space, and can also be translocated to the plasma membrane receptors via adapter proteins 
[Boldin et al., 1996;Colussi et al., 1998;Muzio et al., 1996;Thornberry et al., 1992]. 
Although the first mammalian caspase (caspase-1) was identified as an important  regulator of 
the inflammatory response [Thornberry et al., 1992], at least 7 of the 14 known mammalian 
caspases have important roles in apoptosis. The apoptotic caspases are generally divided into 
two classes: the initiator caspases, which include caspase-2, -8, -9 and -10 and the effector 
caspases, which include caspases-3, -6, -7 [Riedl and Shi, 2004] (see Figure 7).  
All caspases are produced in cells as catalytically inactive zymogens and must undergo 
proteolytic activation during apoptosis. Following a proapoptotic stimulus, they are 
sequentially processed into a precursor, noncatalytic domain and two catalytic subunits: a 
large subunit 20 kDa containing the active site Cys, and a smaller 10 kDa subunit [Yamin et 
al., 1996;Muzio et al., 1998].  Two small and two large subunits are assembled together to 
yield an active caspase enzyme with two active sites [Rotonda et al., 1996;Walker et al., 
1994;Wilson et al., 1994]. Proapoptotic caspases can be generally divided into subclasses with 
either long prodomains or short prodomains present on the nonactivated precursors. The long 
prodomains in the first class contain protein motifs, such as CARD (caspase recruitment 
domains, found in caspase-9 and -2) or DED (death effector domains, found in caspase-8 and 
-10).  
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Figure 7: Diagramatic comparison of all effector and initiator caspases in mammals, fruitflies and 
nematodes. Adapted from http://www.bath.ac.uk/bio-
sci/hejmadi/apoptosis%20&%20caspases%20nrm%20nov04.pdf 
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2.4. FADD/ MORT1 
 
FADD/MORT1 has been originally identified in a yeast two hybrid screen with the CD95 
death domain as a bait [Chinnaiyan et al., 1995;Boldin et al., 1995]. It contains both DD and a 
DED and act as an adapter between DD- containing receptors and the DED- domain- 
containing caspases, namely caspase-8 and caspase-10. It is generally believed that FADD 
binds directly to the death domains of CD95, TRAIL-R1 and TRAIL- R2 by interaction of its 
death domain with the death domains of the receptors. The central role of FADD as an 
adaptor linking death receptors to caspase activation is further supported by experiments 
using cell lines or mouse embryonic fibroblasts (MEFs) deficient in FADD. In these systems, 
FADD has been shown to be essential for recruitment of caspase-8 and caspase-10 not only to 
the CD95 DISC, but also to the TRAIL-R1 and TRAIL- R2 DISCs [Kischkel et al., 
2001;Sprick et al., 2000]. In addition, cells lacking FADD are resistant to CD95-, TNF- and 
TRAIL- mediated apoptosis [Yeh et al., 1998;Juo et al., 1999;Zhang et al., 1998;Kuang et al., 
2000]. Blockage of CD95- and TNF-mediated killing could also be observed when a 
dominant mediated version of FADD was overexpressed [Chinnaiyan et al., 1996].  
Among the death receptors, TNF-R1 differs from CD95 and TRAIL-R1 and -R2. Recruitment 
of FADD to TNF-R1 does not seem to be mediated by direct interacting of the DD of FADD 
with the DD of TNF-R1. Instead it has been proposed that an additional molecule , the TNF-
R1- associated DD- containing protein (TRADD) act as a bridge between TNF-R1 and FADD 
[Boldin et al., 1996;Hsu et al., 1995]. 
 In addition to its function in pro- apoptotic pathways, another possible function for FADD 
was determined by the analysis of mice that either lack FADD in their T cell compartment or 
overexpress a dominant negative version of FADD under a T cell specific promoter [Zhang et 
al., 1998;Kabra et al., 2001;Newton et al., 2000;Newton et al., 1998]. Interestingly, 
lymphocytes derived from these mice are not only resistant to death-receptor-mediated 
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apoptosis, but also show a defect in lymphocyte proliferation. In line with these results, 
FADD has been shown to be phosphorylated by a cell regulated kinase also suggesting a 
connection between FADD and the regulation of cell proliferation [Scaffidi et al., 2000]. This 
idea is further corroborated by a recent publication showing that indeed the reversible 
phosphorylation of FADD is necessary for proper cell- cycle progression in T cells [Hua et 
al., 2003]. 
 
3. Mitogen activated protein kinase family (MAPK) 
 
The highly conserved mitogen activated protein kinase (MAPK) family is one of the major 
kinase families that regulate cells by transducing extracellular signals into cellular response 
[Robinson and Cobb, 1997]. In mammalian systems, these responses include cellular 
proliferation, differentiation, development, the inflammatory response and apoptosis. The 
classic MAPK cascade consists of three sequential intracellular protein kinase activation steps 
and is initiated when the first member, MAPK kinase kinase (MAPKKK) is activated (Figure 
8). MAPKKK is a protein kinase that phosphorylates and activates MAPK kinase (MAPKK), 
and this activation is followed by activation of the specific MAPK.  
MAPKs activate numerous protein kinases, nuclear proteins, and transcription factors, leading 
to downstream signal transduction. Activation of the MAPK cascade is rapid and enables to 
respond to environmental changes in a regulated fashion.  
Three important members of this family are the extracellular signal- regulated kinase (ERK), 
p38 and c-JUN NH2- terminal kinase (JNK). JNK was originally identified as a 54 kDa stress- 
activated protein kinase (SAPK) and is activated in response to many of the stimuli that 
activate p38 such as lipopolysaccharide, TNF, IL-1, osmotic stress and ultraviolet radiation 
[Chen et al., 2001].  
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The JNK protein kinases are encoded by three genes: JNK1, JNK2 and JNK3. JNK1/2 is 
ubiquitously expressed, whereas JNK3 appears to be expressed only in brain, heart and testis. 
 
3.1. Activator protein- 1 (AP- 1)/ c-jun 
 
AP- 1 was one of the first mammalian transcription factors to be identified [Angel and Karin, 
1991], but its physiological function is still being unraveled. AP- 1 activity is induced by a 
plethora of physiological stimuli and environmental insults. In turn, AP- 1 regulates a wide 
range of cellular processes, including cell proliferation, death, survival and differentiation. 
However, despite increasing knowledge regarding the physiological function of AP- 1, the 
target genes mediating these functions are not always obvious. 
AP- 1 is not a single protein, but a menagerie dimeric basic region- leucin zipper (bZIP) 
proteins that belong to the Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1 and Fra2), Maf 
(c- Maf, MafB, MafA, MafG/F/K and Nrl) and ATF (ATF2, LRF1/ ATF3, B- ATF, JDP1, 
Figure 8: Diagrammic representation of the 
mitogen activated protein kinase (MAPK) 
signaling pathway.  
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JDP2) sub- families, which recognize either 12- O- tetradecanoylphorbol- 13- acetat (TPA) 
response elements (5’- TGAG/ CTCA- 3’) or cAMP response elements (CRE, 5’- 
TGACGTCA- 3’) [Chinenov and Kerppola, 2001]. 
C-Jun is the most potent transcriptional activator in its group [Ryseck and Bravo, 1991] 
whose transcriptional activity is attenuated and sometimes antagonized by JunB [Chiu et al., 
1989;Schutte et al., 1989]. It is activated in chemically induced murine liver tumours and 
HCCs of humans [Yuen et al., 2001], suggesting an important oncogenic function for this 
gene in liver tumours of mammals.  
Recently, we demonstrated that the MEKK/JNK pathway operates upstream of the CD95 
pathway to mediate chemotherapeutic drug- induced apoptosis in liver cells via a c-jun 
responsive element [Eichhorst et al., 2000].  
 
3.2. c-jun and apoptosis in tumour cells 
 
The regulation of cell proliferation by AP- 1 might be of crucial importance for the multi- 
stage development of tumours [Liu et al., 2002;Park et al., 1999]. However, AP- 1 does not 
always promote cell proliferation- it also has anti- proliferative activities. The limiting 
components that guide the decision seem to be the Jun proteins, with the Fos proteins has a 
little effect [Shaulian and Karin, 2001].  
C-jun is primarily a positive regulator of cell proliferation, as c-jun- deficient fibroblasts have 
a marked proliferation defect in vitro [Schreiber et al., 1999;Wisdom et al., 1999] and the 
proliferation of c-jun- deficient hepatocytes is severely impaired during liver regeneration in 
vivo [Behrens et al., 2002].  
Early in vitro studies indicated that increased AP- 1 activity can lead to apoptosis in specific 
cell types, including human tumour cells [Shaulian and Karin, 2002]. However, oncogenic 
AP- 1 can antagonize apoptosis in liver tumours [Eferl et al., 2003]. The differential activity 
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of AP-1 in apoptosis is best exemplified by the dual role of c-jun in neuronal cells and 
hepatocytes. Increased c-jun activity promotes apoptosis in neuronal cells in vitro. When the 
activation of c-jun is impaired, either in Jnk3- null or c-jun AA/AA mice, which express a c-jun 
mutant that cannot be activated by JNKs, hippocampal neurons are protected from 
KAINATE- induced cytotoxicity [Behrens et al., 1999;Zhang et al., 2002;Yang et al., 1997b]. 
By contrast c-jun is required for the survival of fetal hepatocytes which undergo apoptosis in 
c-jun- deficient mouse embryos [Eferl et al., 1999]. The cell specific consequence of AP- 1 
activity for apoptosis is probably due to differential regulation of pro- apoptotic and anti- 
apoptotic target genes.  
In neuronal cells c-jun regulates the expression of Bim, a pro- apoptotic BCL2 family member 
that is crucial for neuronal apoptosis [Whitfield et al., 2001]. In T cells, c-jun and c-fos 
regulate the gene that encode Fas Ligand (FasL/CD95L), which can trigger apoptosis through 
the Fas receptor (CD95R) [Kasibhatla et al., 1998]. The crucial pro- apoptotic target gene that 
is repressed by c-jun in tumours might be Trp53 (p53). This has been shown for liver tumours 
that lack c-jun, in which p53 is upregulated and consequently induces apoptosis [Eferl et al., 
2003]. 
The differential regulation of pro- apoptotic and anti- apoptotic genes indicates that AP- 1 can 
promote apoptosis in some tumour types, whereas it induces survival in others. 
 
4. Aim of study 
 
The Hepatocellular carcinoma (HCC) also called hepatoma is one of the most common 
malignancies and has the fourth highest mortality rate worldwide [Coleman, 2003]. 
The major factor for the development of HCC is well defined and some of the steps involved 
in hepatocarcinogenesis have been elucidated in recent years. However, no clear picture of 
how and in what sequence these factors interact at the molecular level has emerged yet. 
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Malignant transformation of hepatocytes occurs in the context of chronic viral hepatitis, 
chronic liver injury, regeneration and as many as 80% of cases occur in cirrhotic livers 
[Ganem and Prince, 2004;Moradpour and Blum, 2005;Wu and Yu, 2007]. The alcoholic liver 
cirrhosis is the leading cause of liver failure. The liver damage progresses gradually from 
hepatic steatosis over steatohepatistis to liver cirrhosis and finally hepatocellular carcinoma. 
Other factors such as the activation of cellular oncogenes and/or inactivation of tumour 
suppressor genes such as the p53 gene affect the genomic instability and may also contribute 
to the development of HCC [Moradpour and Blum, 2005].  
Current available therapeutic modalities for HCC are largely inadequate. Surgical approaches 
such as resection and transplantation are the treatment of choice for HCC; however, because 
of the underlying liver disease, only a minority of patients are suitable for resection, and 
access to transplantation is limited by organ availability. Local tumour ablation is effective for 
early HCC, and chemoembolization is of benefit in intermediate-stage disease. So far, no 
first-line therapy has emerged for advanced HCC. Therefore, research efforts are focused on 
novel targeted therapies.  
Failure to induce cell death in response to apoptotic stimuli is a hallmark of cancer: loss of 
CD95 expression or impairment of the CD95 and TRAIL-receptor pathways is associated 
with dedifferentiation, larger tumour size and poor prognosis, and is a predictor of tumour 
size recurrence [Okano et al., 2003;Ito et al., 2000;Shin et al., 2001;van Noesel et al., 
2002;Ozoren and El Deiry, 2003]. Intervention to influence the sensitivity to programmed cell 
death is therefore a promising therapeutic strategy. 
The significance of c-jun as a major regulator of hepatocyte proliferation and apoptosis 
prompted us to investigate the function of this gene in liver cancer. Previous publications have 
shown that c-jun downregulation sensitizes cells to apoptotic stimuli by inducing the p53 
activity [Eferl et al., 2003]. To better understand how c-jun interferes with hepatocyte 
proliferation/ apoptosis through the CD95 receptor pathway and develop new strategies to 
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prevent liver carcinogenesis, we studied the importance of c-jun loss for 
hepatocarcinogenesis. We developed new siRNA target sequences and showed that: 
 
1.) 20nM of siRNA effectively downregulates c-jun in HepG2 cells 
2.) C-jun downregulation sensitizes HepG2 cells to apoptosis 
3.) The death receptors are relevant in c-jun downregulated HepG2 cells 
4.) Downregulation of c-jun in HepG2 cells increases apoptosis by upregulating of 
CD95 receptor level and preventing FADD phosphorylation 
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II. Material and Methods 
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1. Material 
 
Except where stated differentially, all chemicals were of at least analytical grade and 
purchased from by Sigma-Aldrich (Taufkirchen, Germany), Amersham Biosciences 
(Freiburg, Germany), Serva (Heidelberg, Germany), Merk (Darmstadt, Germany), Invitrogen/ 
Gibco (Karlsruhe, Germany) or Roth (Karlsruhe, Germany) 
 
 
1.1. Common Buffers 
 
PBS (Phosphate buffered Saline): NaCl  137 mM   
 Na2HPO4 8,1  mM  
 KCl  2,7  mM  
 KH2PO4 1,5  mM  
                                      pH = 7,4 
 
TBE (10X): Tris 0,45 M 
 Boric Acid 0,45 M 
 EDTA 10 mM   
 pH = 8,3 
 
Western Running Buffer (10X) Tris 0,25 M 
 Glycin 1,9 M 
 SDS 1%  
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Towbin (10X) Tris 250 mM 
 Glycin 190 mM 
 MetOH 20% 
 
TBST (10X) Tris-base 24,2 g 
 NaCl 80 g  
 pH= 7,6 
 Tween 20 1ml/L 
 
Loading Buffer (5X) SDS 1 g 
 Bromphenolblue 5 mg 
 2 M Tris-HCl 1,5 ml pH= 6,8 
 2- Mercaptoethanol 1,25 ml 
 100 mM EDTA 0,5 ml 
 Glycerol 4,73 ml 
 H2O 1,12 ml 
 
Stacking Acryamid 30% 6,5 ml  
 Bis 2% 2,5 ml  
 Tris-HCl 12,5 ml pH= 6,8 
 SDS 10% 0,5 ml  
 H2O 28 ml 
 
12,5% SDS-PAGE Acryamid 30% 41,6 ml  
 Bis 2% 16 ml  
 Tris-HCl 25 ml pH= 8,8 
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 SDS 10% 1 ml  
 H2O 16,4 ml 
    
Protein Lysis Buffer: Tris-HCl 20 mM     pH = 7,4 (4°C) 
 NaCl 130 mM 
 Glycerol 10% (w/v) 
 Triton X-100 1% (w/v) 
 1 x Complete Protease Inhibitors (Roche) 
 EDTA 2 mM 
 NaF 500 mM 
 Na3VO4 10 mM 
 
Homogenization Buffer: Sacchorose 250 mmol/l 
 Tris 20   mmol/l 
 EGTA 2     mmol/l   
            pH = 7,5 (4°C) 
 PMSF 200 mM (in 2-Propanol) 
 Aprotinin 5 mg/ml (in water) 
 Leupeptin 10 mmol/l (in water) 
 2- Mercaptoethanol  0,7 µl/ml 
 
Stripping Buffer: 62,5 mM  Tris-HCl 250 ml    pH= 6,7 
 SDS   5 g   
            2- Mercaptoethanol 1760 µl 
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Nicoletti Buffer: Sodiumcitrat 0,1 % (w/v) 
 Triton X-100 0,1 % (w/v) 
 Propidiumiodid 50 µg/ml 
 
Freezing medium FCS 90% 
 Dimethylsulfoxid  10% 
  
 
1.2. Real Time PCR- Primer 
 
 
All primers were purchased from Metabion (Martinsried), MWG Biotech or Thermo. 
 
 
 
 
Name forward Reverse Product 
c-jun 5’ TGG AAA CGA CCT TCT 
ATG ACG AT 3’ 
5’ CTG TAG CCA TAA GGT 
CCG CTC T 3’ 
70 bp 
CD95 5’ GCC CAA GTG ACT GAC 
ATC AA 3’ 
5’ CAG GCC TTC CAA GTT 
CTG AG 3’ 
84 bp 
FasL 5’ GGC CTG TGT CTC CTT 
GTG AT 3’ 
5’ TGC CAG CTC CTT CTG 
TAG GT 3’ 
99 bp 
Gapdh 5’ ACC CAC TCC TCC ACC 
TTT GA 3’  
5’ CTG TTG CTG TAG CCA 
AAT TCG T 3’ 
100 bp 
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1.3 RNAi Primer 
 
Name sense Antisense Purchase 
jun4 siRNA  5’ AAA AAA GGA AGC 
TGG AGA GAA T 3’ 
5’ ATT CTC TCC AGC 
TTC CTT T 3’ 
Ambion 
AM1620 
jun siRNA 5’ AAA AAA GGA AGC 
TGG AGA GAA T 3’ 
5’ ATT CTC TCC AGC 
TTC CTT T 3’ 
Ambion 
AM16104 
ctrl siRNA 5’ AAG GCT ACG TCC 
AGG AGC GCA 3’ 
5’ AAT GCG CTC CTG 
GAC GTA GCC 3’ 
Ambion 
 AM16104 
Caspase-8 
siRNA 
Sequence unknown Sequence unknown Dharmacon  
M-003466-04 
juns siRNA Sequence unknown Sequence unknown Dharmacon   
M-003268-02 
jun1 siRNA 5’ AAC GCC TCG TTC 
CTC CCG TCC 3’ 
5’ AAG GAC GGG AGG 
AAC GAG GCG 3’ 
Ambion  
AM1620 
jun11 siRNA 5’ AAC TTC AAC CCA 
GGC GCG CTG 3’ 
5’ AAA CTG CGT TAG 
CAT GAG 3’ 
Ambion 
AM1620 
jun20 siRNA 5’ AAC TCA TGC TAA 
CGC AGC AGT 3’ 
5’ AAA CTG CTG CTG 
TAG CAT GAG 3’ 
Ambion  
AM1620 
 
 
1.4 Antibodies 
 
Name kDa Purchase Order Number 
c-jun 39 BD Biosciences Pharmingen 610326 
phospho- cjun 
(Ser 63) 
48 Cell signalling (New England 
Biolabs) 
9261 
CD95 (Fas C-20) 48 Santa Cruz Biotechnology sc-715 
FasL 45 BD Biosciences Pharmingen 556387 
phospho- FADD 
(ser 194) 
28 New England Biolabs 2781S 
FADD (518) 30 Santa Cruz Biotechnology sc-6035 
Actin 40 ImmunO (MP Biomedicals) 691001 
Gapdh antibody 
[6C5] 
36 abcam ab8245 
E- Cadherin 120 BD Biosciences 610181 
caspase 8  were a kind gift from Peter 
Krammer 
[Krueger et al., 2001;Scaffidi 
et al., 1998]. 
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1.5 Reagents 
 
Leucine zipper tagged CD95 Ligand (LZCD95L) was a kindly gift from Prof. Dr. Peter H. 
Krammer (DKFZ Heidelberg) and have been described previously [Kuntzen et al., 2005]. The 
death receptor ligands TRAIL (APO-2L) and TNF-α, to stimulate the specific receptors were 
purchased from Sigma and 5-FU and Actinomycin D were purchased from Sigma-Aldrich 
 
 
 
1.6 Cell lines  
 
The HepG2 cell line derived from hepatocellular carcinoma and is sensitive to CD95- induced  
apoptosis. Huh7 cell line is also derived from hepatocellular carcinoma and shown to express 
p53 with half- life as a result of point mutation at codon 220 [Hsu et al., 1993]. All cell lines 
are a kindly gift from Peter Krammer. 
All cells were cultured in RPMI 1640 medium (PAA laboratories) supplemented with 10% 
FCS (PAA laboratories) and 1% penicillin/ streptomycin (Gibco/ BRL) in a humidified 
atmosphere at 5% CO2 and 37 °C. 
For transfection experiments OptiMEM I + Glutamax I (Gibco) were used. 
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2. Methods 
 
2.1 Cell culture techniques 
 
2.1.1 Freezing and thawing 
 
For long- term storage, passages 1-10 were stored in liquid nitrogen while higher passages 
were kept at -80 °C. Since ice crystals forming during the freezing and process could rupture 
the cells, a special freezing medium was used (see section 1.1 Common Buffers). 
Cells were centrifuged at 1200 rpm for 5 min, resuspended in freezing medium at a 
concentration of 5 x 105 cells (1 ml per cryovial) and frozen at – 20 °C for one day. 
Afterwards, they were transferred to – 80 °C and, if desired, after another day to liquid 
nitrogen. 
For thawing: cells were thawed in a warm water bath (37 °C) and transferred to a  centrifuge 
tube with 10 ml prewarmed complete medium. Centrifugation was performed at 1200 rpm for 
5 min. Afterwards, the cell pellet was dissolved in 30 ml prewarmed complete medium. The 
culture was left to grow for at least three days before any experiments. 
 
2.1.2 Determination of cell concentration 
 
To determine the cell number, cells were washed once with 5ml PBS and 1 ml of trypsin was 
added to the cells. The cells were incubated for approx. 5 min in the incubator, and 
resuspended in prewarmed medium.Cells were diluted 1:2 with Trypan blue (Gibco/ BRL) 
and were counted in a Neubauer counting chamber to determine the number of cells per ml 
suspension. 
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2.1.3 Splitting and seeding  
 
Cells were split every two to three days and diluted to 1:2.  
For experiments, cells were seeded a day before transfection in 6- well plates at a density of 1, 
5 x 105 cells. The cell suspension was centrifuged at 1200 rpm for 5 min and resuspended in 
prewarmed medium. After determining the cell density, the appropriate concentration was 
adjusted by dilution in prewarmed medium. 
 
 
2.2. Light microscopy 
 
Morphologic changes of apoptotic cells such as shrinking, blebbing and formation of 
apoptotic bodies can be detected by visualization in a light microscope. 
Cells at a concentration of 1, 5 x 105 (6- well plate) were either transfected with ctrl. siRNA 
or jun siRNA for 30 hours. After incubation, probes were viewed with light optical 
microscope (Zeiss) at 10 X magnification and pictures were taken with the connected camera. 
 
2.3. Measurement of apoptosis by flow cytometry 
 
Flow cytometry allows one to measure, with high accuracy, relative quantities of a variety of 
cell constituents simultaneously. When the measurements are recorded in a list mode, it is 
possible to attribute each of the several measured features to a particular cell and thus to 
obtain correlated measurements of these features on a cell by cell basis. Cellular heterogeneity 
can thus be estimated and subpopulations with distinct characteristics can be discriminated. 
Thus, multiparameter flow cytometry offers improved opportunities to describe the complex 
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relationships between cell activation, proliferation, differentiation, maturation and 
decomposition within heterogeneous cell populations as e.g., blood and bone marrow where 
different differentiation lineages are mixed together, or tumours where malignant cells may be 
discriminated by clonal characteristics. 
Cells were scraped with a rubber policeman and washed once with cold PBS (1200 rpm, 5 
min). The pellets were resuspended in 200µl nicoletti buffer and left overnight at 4 °C in the 
dark. Untreated cells were used for adjustment of instrument settings. The fluorescence 
intensity (FL-2) as well as scatter parameters was acquired. The percentage of apoptotic cells 
was determined from the region of the subG1 peak.  
Measurement was performed in a flow cytometer (FACS Calibur Becton Dickinson, 
Heidelberg, Germany) using Cell Quest as software 10,000 events were counted. Specific rate 
of apoptosis was calculated as (rate probe-rate control)/ (100%- rate control). 
 
2.4. RNAi 
 
RNA interference (RNAi) is a well- recognized pathway involved in cellular defense against 
viral invasion, transposon expansion, and post- transcriptional regulation [Zamore, 
2001;Tuschl, 2001;Sharp, 2001;McManus and Sharp, 2002;Hannon, 2002;Hutvagner and 
Zamore, 2002]. As a novel biological pathway, RNAi has quickly distinguished itself as a 
valuable reverse genetic tool. The functional intermediates in the RNAi pathway, small 
interfering RNA (siRNAs), may be synthesized by a variety of means and introduce 
intracellularly to effect changes in gene function.  
For transient transfection, Oligofectamine TM (Invitrogen) was used according to the protocol 
of the manufacturer. 1.2 x 105 cells were seeded in 12 wells 24 hours prior to transfection in 
RPMI with FCS without antibiotics. Transfection was carried out in OptiMEM (Gibco) 
without FCS, which was added after 4 hours. 
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One and a half days later (approx.30 h), cells were washed with cold PBS and either harvested 
for analysis or stimulated for further 16 h. Cells were pooled and 50% were used for flow 
cytometry analysis and Western blot respectively. 
 
2.5. Western blot analysis 
 
Agarose gels are best for separating larger molecules, like DNA, sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) is better suited for running smaller ones, 
like proteins. Sodium dodecyl sulphate is an anionic detergent that binds quantitatively to 
proteins, denaturing them linearity and uniform charge, so that they can be separated solely on 
the basis of their size.  
Western analysis was carried out as follows. Briefly, proteins were separated by SDS-PAGE 
and transferred to PVDF (Millipore) membranes. Membranes were blocked for one hour in 1 
x TBS solution containing 0,1% Tween 20 (TBS-T) and 5% milk powder. Membranes were 
then incubated with primary antibodies in TBS-T and 5% milk powder at 4°C overnight, 
followed by the appropriate HRP-conjugated secondary antibody for one hour at room 
temperature. Western blots were developed using the ECL system from Amersham.  
 
2.5.1 Protein determination 
 
The method developed by Bradford [Bradford, 1976] makes use of the feature of Coomassie 
Brilliant Blue G- 250 to change its absorption maximum from 465 nm to 595 nm on binding 
to proteins. The protein content of the lysates can thus be quantified by comparing the 
absorption with a calibration curve prepared with increasing concentrations of BSA. 
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Measurement was performed in Photometer Ultraspec 3100 pro (Biochrom) Cell lysates were 
diluted 1:500 in H2O containing Bradford solution (1:5 diluted). 5 minutes were allowed for 
the color shift to develop. Samples were measured at 592 nm. 
Cells were seeded in 6- well plates (1, 5 x 105) and were incubated over night. The next day 
cells were transfected with siRNA (see section 2.4.) incubated for 30 hours and either left 
untreated or stimulated for 16 hours. For harvest, three wells were pooled and cells 
centrifuged at 1400 rpm, 4 °C for 5 minutes. The pellet was washed in cold PBS. After 
another centrifugation step, the pellets was resuspended in approx. 50 µl protein lysis buffer 
(depending on pellet size) and were at regular intervals shake at 4 °C for 30 minutes. The 
solution was cleared by centrifugation (1400 rpm, 4 °C, 5 minutes) and the protein solution 
was transferred to fresh tubes. Protein determination was performed following the protocol of 
Bradford (see section 2.5.1.). The protein solution was diluted with 5 x loading buffer, boiled 
at 95 °C for 3 minutes and used directly for electrophoresis or stored at – 20 °C. 
 
 
2.5.2 Membrane Stripping 
 
In order to detect different proteins on a given PVDF membranes, bound antibodies from 
previous experiments have to be removed. For that purpose, membranes were immersed in 
stripping buffer and treated for 30 minutes at 50 °C on a shaking platform. Subsequently, 
remnants of stripping buffer were washed away by three washing steps in TBS-T (10 min at 
room temperature). Stripping efficiency was confirmed by applying ECL solution (see section 
2.5). When no bands became apparent the membrane was blocked again to cover unspecific 
binding sites with 5 % non-fat dry milk in TBS- T for 1 h at RT. Afterwards, the next primary 
antibody was applied. 
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2.6. RNA-Isolation and Reverse transcription 
 
Obtaining high quality, intact RNA is the first and often the most critical step in performing 
many fundamental molecular biology experiments, including Northern analysis, nuclease 
protection assays, RT-PCR, RNA mapping, in vitro translation and cDNA library 
construction.  
1 µg of total RNA was reverse transcribed using Moloney murine leukaemia virus reverse 
transcriptase (MMLV) (Life technologies) with oligo(dT)15 primers (Roche) in a 20 µl 
reaction tube containing 10 mM DTT and 500 µM desoxynucleotide triphosphates. One µl 
aliquots were amplified in a DNA thermocycler (MJ Research) with 0, 5 units of Taq DNA 
polymerase (Roche) in a 50 µl reaction. Thirty reaction cycles were performed. Each cycle 
consisted of a denaturation step (94°C for 30 s), an annealing step (54°C for 30 s) and an 
elongation step (72°C for 10 min). PCR products were analysed in agarose gels.  
 
 
2.7. Real Time PCR   
 
Real-time RT-PCR was performed on a Rotorgene 3000 (Corbett Research, Sydney, 
Australia) using heat-activated Taq DNA polymerase (Amplitaq Gold; Applied Biosystems). 
After an initial activation phase(for the Taq polymerase) of 5 min at 95°C, the samples were 
cycled 40 times at 95°C for 10 s and 60°C for 10 s and 72°C for 30 s. Target gene forward 
and reverse primers and probes were designed using Primer Express 1.5 software (Applied 
Biosystems, Foster City, CA). Commercially available predeveloped TaqMan assay reagents 
were used for the internal standards human glyceraldehyde-3-phosphate-dehydrogenase 
(GAPDH) and 18S ribosomal RNA (18 S rRNA). All primers and probes were obtained from 
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Applied Biosystems. All primers were cDNA specific, not amplifying genomic DNA. The 
following sequences of oligonucleotide primers were used (see Primer list 1.2). 
 
 
3.15. Statistics 
 
Statistical analysis was performed using the SPSS software (version 11.0; SPSS, Inc., 
Chicago, IL, USA). Data are generally given as mean ± standard deviation, if not otherwise 
stated. Student t test was used for paired data. Mean differences of non-parametric data were 
analyzed by the Mann-Whitney U test. Significance was assessed using a Monte Carlo 
approach with a post-hoc Bonferroni correction. A difference was considered to be 
statistically significant at p < 0.05. 
 
2.8. Densitometrie software 
Densitometrie analysis was carried out using TINA software Version 2.0 (Raytest, Germany) 
 
2.9. Membrane protein isolation   
 
After siRNA transfection (see section 2.4) cells were scraped with a rubber policeman and 
washed once with cold PBS (200 x g, 2 min, 4°C). The pellets were resuspended in 
homogenisation buffer and sonicated for 10 s. After a second centrifugation step (800 x g for 
2 min at 4°C) the supernatant were transferred in a new tube which stored at -80°C over night. 
The next day, homogenate was thawed and transferred in a ultracentrifugation tube and 
ultracentrifugated (Beckman Airfuge Rotor A110) at 25 psi for 8 min. After centrifugation the 
supernatant ( the cytosolic fraction) were transferred in a new tube and the pellet (membrane 
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fraction) were refilled with homogenisation buffer, resuspend. Protein measurement was 
made for both fractions using the photometer. 
 
 
2.10 Luciferase Reporter Assays 
 
The purpose of the reporter gene assay is to measure the regulatory potential of an unknown 
DNA-sequence.  
HepG2 cells were transiently transfected with siRNA. After 24 h cells were transfected again 
with 0,4 µg of Vector DNA (pcH110) and 1 µg of firefly- Luciferase Vectors. The pCH110 
vector encodes the β-galactosidase gene under the control of the SV40 promoter (Amersham 
Biosciences), which was used as an internal control for transfection efficiency. After 24 h, 
cells were scraped and washed with cold PBS. The pellet were resuspended in 100 µl 
Repoterlysisbuffer and stored at -80°C for at least 24 h. The next day, cells were thawed at 
RT, vortexed and centrifuged (14.000 rpm, 10 min, 4°C). Supernatant transferred in a new 
tube and luciferase activities were determined in duplicate samples as described by the 
manufacturer (Promega GmbH). Luciferase values (RLU) were calculated by dividing the 
luciferase activity by the β-galactosidase activity. The data represent means ± SD of three 
independent experiments performed in duplicates. 
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III. Results 
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1. 20 nM of siRNA effectively downregulates c-jun in HepG2 cells  
 
 
Up to now, mainly two techniques were used for knock-out experiments. One is based on the 
replacement of a specific wildtype gene by a mutated and often non-functional allele on the 
genomic level by means of homologous recombination. This technique is very stable but 
relatively time consuming (>1 year). Another approach which yields much faster results 
makes use of antisense oligodeoxynucleotides. Advantages of the antisense method are that it 
is easy, high-throughput and applicable to genes essential for cell growth. However, the 
method had a disadvantage that silencing efficacy is sometimes too low to analyze gene 
function.  
In this context, RNAi seems to be a good alternative to study gene functions. Recently 
published protocols provide information for the production of siRNA using simple molecular 
biology techniques [Elbashir et al., 2001a;Elbashir et al., 2001b]. 
Blast search was used to find potential siRNA target sequences targeting c-jun and the same 
method was used to create a negative control (ctrl siRNA) not containing any mammalian-
gene coding sequence (For sequence see section 1.3. in Materials).  
In order to show that self synthesized siRNA is able to downregulate c-jun in vitro, HepG2 
cells were separately transfected as described in the method section, with four different self 
synthesized in vitro transcribed siRNA (designed as: jun1-, jun11-, jun20- and jun4 siRNA) 
and with a pool of the same siRNA sequences. For creating self synthesized siRNA we used 
29-mer DNA oligonucleotide with 21 nt encoding the siRNA and 8 nt complementary to the 
T7 Promoter Primer. 
Western Blot analysis shows that only jun4 siRNA was able to decrease the expression level 
of c-jun to a significant amount in vitro (Figure 1A). Western blot analysis was also used to 
compare the effect of cells transiently transfected with the in vitro synthesized jun4 siRNA 
sequence with the transfection of the same sequence produced by chemical synthesis 
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(designed as jun – Ambion cat. AM16104) or with a pool of different chemically synthesized 
sequence commercially available (designed as juns – Dharmacon cat. M-003268-02). Western 
Blot analysis shows that jun siRNA as well as juns siRNA was able to decrease the expression 
level of c-jun (Figure 1B) and proved also to abolish the amount of phosho- c-jun, showing 
that siRNA transfection is effective in reducing the active form of jun (Figure 1C). Effective 
silencing effect of jun siRNA transfection was also assessed at the transcription level by Real 
Time-PCR (Figure 1D) which confirmed abolished levels of c-jun in cells transfected with 
the aforementioned sequences but not in cells transfected with the ctrl siRNA sequence. 
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Figure 1A: siRNA downregulates c-jun in HepG2 cells and affect phospho c-jun.  
HepG2 cells were transfected with siRNA targeting c-jun compared to 20 nM control siRNA (ctrl siRNA). The 
first band indicates mock (m) transfected HepG2 cells. Western blot analysis shows the downregulation of c-jun 
in HepG2 cells by jun4 siRNA and by the pool of siRNA (last band) transfected cells. β-Actin was used as 
loading control. B: HepG2 cells were transfected with either 20 nM jun siRNA (chemically synthesized) or with 
a pool of siRNA targeting c-jun (juns siRNA (smartpool (Dharmacon): 5 nM each, juns siRNA) to compare the 
difference between both. No difference was shown between both variants of siRNA. C: HepG2 cells were 
transfected with 20nM siRNA against c-jun (juns siRNA, jun siRNA) compared with 20 nM control siRNA 
(ctrl.siRNA) transfected cells. siRNA targeting c-jun shows also to abolish the amount of phospho-c-jun. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To further assess also at the functional level the effect of c-jun inhibition, a reporter assays for 
the AP1-transcriptional activity was performed (Figure 2). This investigation showed a 
remarkable decrease of the AP1-transcriptional activity only in cells treated with coding 
siRNA sequences, hereby confirming the efficacy of our self-synthesized siRNA to 
investigate the functional effects of c-jun inhibition.  
Figure 1 
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As no difference could be observed between the both sequences (jun siRNA and juns siRNA) 
the known siRNA sequence (jun siRNA) was chosen for further experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Luciferase Reporter assay shows a functional repression of c-jun in HepG2 cells. 
HepG2 cells were cotransfected with a luciferase reporter plasmid under the control of four repeat sequence of 
TRE DNA element followed by a collagenase promoter and pCH110 vector harboring the ß-galactosidase cDNA 
(internal standard) using the Fugene Reagent according to manufacturer protocol (Roche Diagnostics, 
Indianapolis, IN). Twenty-four h after transfection, cells were lysed. Luciferase expression was measured using 
the luciferase assay system (Promega) according to the manufacturer’s protocol. Reporter activity was 
normalized for transfection efficiency using ß-galactosidase. 
Figure 2: Downregulation of c-jun by siRNA 
on mRNA level. 
mRNA level of c-jun were determined by 
realtime-PCR. The expression levels are given 
as ratio to control primer (Gapdh). 
The experiment confirmed the downregulation 
of c-jun on a transcriptional level using siRNA 
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Figure 4: Downregulation of c-jun via siRNA in HepG2 cells completely abolished the 
function over 5 days. 
HepG2 cells were transiently transfected with siRNA targeting c-jun or crtl. siRNA. Expression 
of c-jun was analyzed by western blot at the indicated time points. β-Actin was used as as 
loading control. The intensity of the signals was measured densitometrical and the rations of c-
jun vs. actin signals are displayed. 
To assess the stability of c-jun inhibition in our system by assessing c-jun expression by 
Western blot in HepG2 cells, a time-kinetic study of c-jun inhibition was performed over 
seven days after transfection. As shown in Fig. 4, expression levels of c-jun were completely 
abolished 12 hours after transfection (Figure 4). The expression level of c-jun in jun siRNA 
transfected HepG2 cells increases between days 5 to 7 (120-168 h after transfection) in 
comparison to ctrl siRNA-transfected HepG2 cells and achieved control level at day 7 (168 
h). Therefore, all experiments were realized in this time frame (up to 7 days). In summary, we 
could successfully synthesize a form of c-jun-targeting siRNA which proved effective and 
stable in HepG2 cell line abolishing the function of c-jun over 5 days. Also, we showed 
siRNA transfection resulted in 12,4-fold decrease of c-jun expression as judged by Western 
blot analysis. 
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2. C-jun downregulation sensitizes HepG2 cells to apoptosis 
 
C-jun has been shown to have positive, negative or no influence on apoptosis under different 
experimental conditions [Leppa and Bohmann, 1999;Mak and Yeh, 2002]. Increased c-jun 
activity promotes apoptosis in neuronal cells in vitro. In contrast, c-jun is required for the 
survival of fetal hepatocytes, which undergo apoptosis in c-jun deficient mouse embryos 
[Eferl et al., 1999;Behrens et al., 2002]. Therefore the function of c-jun in relation to 
apoptosis needed further investigation. 
To assess how c-jun inhibition affects apoptosis in our system, HepG2 cells were transfected 
with jun siRNA or ctrl siRNA as described, and the apoptosis rate was measured by flow 
cytometry [Nicoletti et al., 1991]. As shown in Fig. 5, c-jun-transfected cells showed a mild 
but significant increase in apoptosis compared to untreated cells (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Downregulation of c-jun in HepG2 cells shows a significant higher 
apoptosis rate than control cells 
HepG2 cells were transfected with control and jun siRNA 30 hours before harvest. 
Mesurement of apoptosis were performed after nicoletti treatment by flow cytometry. 
Untreated (control) and mock treated cells were also measured for apoptosis,* P= 0,006 
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Consistently, as we analyzed the cell morphology, apoptotic features could be seen (Figure 
6A,B).  Therefore downregulation of c-jun in HepG2 cells lead to spontaneous apoptosis up to 
20% compared to control cells. This experiment suggests that c-jun has a protective function 
against apoptosis in HepG2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
3.  The death receptors are relevant in c-jun downregulated HepG2 cells 
 
Loss of sensitivity to apoptosis is a hallmark of cancer leading to cell immortalization 
[Eichhorst and Krammer, 2001]. The way how cells lose their ability to undergo apoptosis is 
thought to occur through several mechanisms which include loss of the death receptors CD95 
or TRAIL-receptor. To study the influence of c-jun on death receptor mediated apoptosis we 
stimulate several membrane receptors in hepatoma cells, known to be able to induce 
apoptosis. To this aim leucine zipper-tagged CD95 ligand (LZCD95L) TRAIL or TNFα was 
used. While stimulating cells with TNFα, Actinomycin D was added to enhance its pro-
apoptotic effect. To assess the influence of c-jun inhibition on the sensitivity to receptor-
mediated apoptosis in these cells substances were administered in different concentrations in 
cells transiently transfected with jun siRNA or with ctrl siRNA. Initially, cells were treated 
Figure 6A,B: Downregulation of c-jun in HepG2 cells show apoptotic features 
Microscope analyses show HepG2 cells B treated with ctrl.siRNA and C treated with jun siRNA. Both probes 
were viewed with light optical microscope at 10 X magnification. 
. 
B C 
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with different concentrations of the leucine zipper-tagged CD95 ligand (LZCD95L) and 
TRAIL 30 hours after transfection of these cells with jun siRNA (Figure 7 and 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addition of TRAIL or CD95L led to a dose-dependent increase of apoptosis in ctrl siRNA 
transfected cells. However, the increase of apoptosis rates in jun siRNA transfected cells after 
stimulation with CD95L or TRAIL was higher than that observed in ctrl siRNA transfected 
cells (Figure 7 and 8). The difference between apoptosis rates in ctrl- and jun- siRNA 
tranfected cells after stimulation was higher than that achieved by jun siRNA transfection 
alone. These findings suggested, that c-jun inhibition facilitates the transmission of the pro-
apoptotic signal in the cells, hereby synergistically increasing apoptosis after membrane 
receptor stimulation. Since this effect was better to be seen at a concentration of 10 ng/ml 
LZCD95L or 2,5 ng/ml TRAIL, this concentrations were used for further experiments.  
 
 
Figure 7: Effect of c-Jun inhibition and concomitant stimulation of CD95 in cancer cells on 
apoptosis. 
 HepG2 cells were transfected either with ctrl- or c-jun siRNA. 30 hours later, cells were 
stimulated with the indicated dose of LZCD95L. The apoptosis rate was measured by flow 
cytometry using propidium iodide, * P=0,016;** P=0,014;*** P=0,001;**** P=0,002. 
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SiRNA transfection without any administration of death receptor stimulating substances 
(control) for 16 hours induced 10% apoptosis in cells transfected with ctrl siRNA and 23% in 
jun siRNA transfected cells (Figure 9). Downregulation of c-jun in HepG2 cells with 
concomitant application of LZCD95L and TRAIL however, dramatically increased apoptosis 
rates up to 70% indicating that c-jun acts to suppress the CD95- and TRAIL mediated 
apoptosis signalling pathways (Figure 9).  
The TNF receptor stimulation is known to activate both, a survival and a death signalling 
pathway, resulting in most cancer cells, in no effect on apoptosis. The survival pathway is 
represented by the TNFα mediated activation of NF-kappa B, which is known to activate 
antiapoptotic signalling. The death signalling pathway is recruited by FADD, procaspase8, 
cFLIP and procaspase 10. 
 
Figure 8: Effect of c-jun inhibition and concomitant stimulation of TRAIL in cancer cells on 
apoptosis. 
HepG2 cells were transfected either with ctrl- or jun siRNA. 30 hours later, cells were stimulated 
with the indicated dose of TRAIL. The apoptosis rate was measured by flow cytometry using 
propidium iodide, * P=0,02; ** P<0,001. 
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To obtain an overall proapoptotic effect by the stimulation of cells with TNFα, Actinomycin 
D (Act.D), an inhibitor of nucleic acid synthesis which is thought to shift the balance of TNFα 
toward a proapoptotic effect by inhibiting the transcriptional activity bound to NFκB 
activation, was administered in a concentration of 100 ng/ml. The TNFα +Act.D treated cells 
do not show a significant difference between ctrl and jun siRNA transfected cells (Figure 9). 
To further investigate whether the apoptosis-enhancing effect of c-jun downregulation in liver 
cells is specific for death receptor mediated signaling pathway, cells transfected with jun 
siRNA were stimulated with the chemotherapeutic agent 5-FU, a reagent that causes apoptosis 
in vitro that is partially mediated via the CD95 system and is caused by up-regulation of 
CD95 and CD95L [Muller et al., 1997;Eichhorst et al., 2001;Tillman et al., 1999]. On the 
bases of these data, HepG2 cells after c-jun downregulation, were treated with 100 µg/ml 5-
FU and the apoptosis rate was determined by flow cytometry analysis. We observed, that c-
jun downregulation and concomitant application of 5-FU also showed a significantly higher 
apoptosis rate than the control cells, suggesting that the transcription factor AP-1 acts to 
suppress the CD95 mediated apoptosis signaling pathway trough the anticancer drug 5-FU 
(Figure 9). 
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Figure 9: c-jun downregulation and concomitant application of apoptosis inducing substances in HepG2 
cells induces significant higher apoptiosis rate than the control cells 
HepG2 cells were transfected with either control- or jun siRNA and were stimulated 30 hours after siRNA 
transfection with indicated dose of LZCD95L, TRAIL, and 5-FU. The apoptosis rate was measured by flow 
cytometry. HepG2 cells treated with TNFα+Act.D do not show a difference between control- and c-jun siRNA 
treated cells, ns P=0,802; * P<0,001. 
Figure 10: Kinetic analysis showed a specific effect of apoptosis in HepG2 cells after 
downregulation of c-jun and concomitant application of TRAIL 
HepG2 cells were transfected with either ctrl- or jun siRNA and were stimulated 30 hours after 
transfection with indicated dose of TRAIL. The apoptosis rate was measured by Facs after 
indicated time. 
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Kinetic analysis of the apoptosis rate with ctrl- and jun siRNA and concomitant receptor 
specific ligand TRAIL treated cells showed that the effect of apoptosis is specific. It can be 
detected after 8 hours with a difference of approx. 20% (by TRAIL application). The 
apoptosis level of ctrl- and jun siRNA treated cells reached the same level after 24 hours 
(Figure 10). We assume, after 24 h the apoptosis effect is not specific, because the effect of c-
jun-/ctrl siRNA prevails over the application of TRAIL. 
To elucidate the role of CD95 receptor for c-jun dependent sensitization to apoptosis, we used 
Huh7 cells, a hepatocellular carcinoma cell line. These cells can not express the CD95 
receptor due to mutated p53 as a result of a point mutation at codon 220 [Hsu et al., 1993] and 
therefore represent a cell line to address this question [Muller et al., 1998].  
Huh7 cells were treated with jun siRNA as described for HepG2 cells. We observed a 
significantly higher apoptosis rate in c-jun downregulated cells both in CD95L, TRAIL and 5-
FU stimulated cells compared to ctrl siRNA treated cells (Figure 11). The unstimulated 
(control) cells showed the same effect. The apoptosis rate is significantly higher in c-jun 
downregulated Huh7 cells compared to crtl siRNA treated cells. In contrast to HepG2 cells 
the apoptosis rate was generally lower. Huh7 cells with concomitant application of siRNA 
and TNFα+ Act.D did not show a difference in apoptosis rate (Figure 11), thus confirming, 
that TNFα death receptor pathway uses a different signalling pathway than CD95 or TRAIL.  
We also observed a significant increase in apoptosis rate in Huh7 cells, which were 
concomitantly, treated with 5-FU and jun siRNA compared to crtl siRNA and 5-FU treated 
cells. However, the apoptosis rate was also lower in Huh7 cells compared to HepG2 cells. A 
functional lack of CD95 receptor in TNFα treated Huh7 cells however, does not affect the 
apoptosis rate. This shows again, that the TNFα induced death pathway act completely 
different than the CD95 or the TRAIL pathways.  
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According to this observation protein isolation has been carried out in c-jun downregulated 
HepG2 cells and the level of p53 was determined (Figure. 12) 
Unlike earlier observations [Kuntzen et al., 2005;Eferl et al., 2003], p53 protein level was not 
increased in HepG2 cells, suggesting that p53 is not responsible for the increase in sensitivity 
to receptor induced apoptosis. 
 
 
 
 
 
 
 
Figure 11: c-jun downregulation and concomitant application of apoptosis inducing substances in HuH7 
cells induces significant higher apoptiosis rate than the control cells 
Huh7 cells were transfected with either control- or jun siRNA and were stimulated 30 hours after siRNA 
transfection with indicated dose of LZCD95L, TRAIL, and 5-FU. The apoptosis rate was measured by flow 
cytometry. HuH7 cells treated with TNFα+Act.D do not show a difference between control- and c-jun siRNA 
treated cells, ns P=0,6334; * P<0,001; ** P=0,017 
 
Figure 12: c-jun downregulation in 
HepG2 cells do not show an increase 
of p53 level 
HepG2 cells were transfected with either 
ctrl- or jun siRNA and protein isolation 
with westernblot was performed. Actin 
was used as loading control. 
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Taken together, these results suggest that c-jun enhances not only the apoptosis ratio in 
HepG2 cells, but is specific for death receptor-mediated apoptosis. Furthermore, p53 protein 
level was not increased in these cells, suggesting that the increased sensitivity to receptor 
mediated apoptosis is not p53 dependent. 
4. Downregulation of c-jun in HepG2 cells increases apoptosis by 
upregulating of CD95 receptor level and preventing FADD phosphorylation 
 
In order to investigate the involvement of caspase-8 in signal transduction, cleavage products 
of caspase-8 were analyzed by Western blotting, after c-jun downregulation and concomitant 
stimulation with leucine zipper-tagged CD95 Ligand (LZCD95L) [Kuntzen et al., 2005]. 
Cleavage of caspase-8 produces two intermediates (p42 and p44) which are further processed 
to the active 20 kDa fragment. The increase of apoptosis as measured by flow cytometry in c-
jun downregulated cells, corresponded to an increase of caspase-8 activation, as judged by its 
cleaved active subunits (Figure 13).  
 
 
 
 
Figure 13: Western blot analysis shows an increase of caspase-8 activation in c-jun downregulated 
HepG2 cells after 8 hours 
HepG2 cells transfected with either ctrl- or jun siRNA and stimulated 30 hours after transfection with the 
indicated dose of LZCD95L. Total cell lysates were prepared at the indicated time points and caspase-8 
expression was analyzed by immunoblotting. Westernblot analysis has been carried out. β-Actin was used as 
a loading control. 
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To investigate whether c-jun inhibits the CD95 signalling pathway upstream or downstream 
of caspase 8, we co-transfected HepG2 cells with jun and caspase-8 (casp8) siRNA (Figure 
14).  
Co- transfection of HepG2 cells with casp8 siRNA abolished the effect of c-jun 
downregulation after receptor stimulation, suggesting that c-jun acts upstream of caspase 8, 
likely on the CD95 or DISC level (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moreover, the cleaved fragment of caspase-8 (p20) is visible in c-jun silenced HepG2 cells, 
which confirmed our assumption, that c-jun inhibits CD95 signalling pathway upstream of 
caspase-8 (Figure 15). 
 
 
Figure 14: Increased apoptosis rate after downregulation of c-jun in HepG2 cells is mediated by caspase-8  
HepG2 cells were transfected with either ctrl- or jun siRNA and were stimulated 30 hours after siRNA 
transfection with indicated dose of LZCD95L. Flow cytometry analysis was performed, * P<0,001; ns P=0,225 
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Since c-jun caused an increase of caspase-8 cleavage product, we evaluated whether this 
might be due to increased expression of CD95 receptor. First, we verified the mRNA level of 
CD95 receptor using RT-PCR method. This clearly showed an upregulation of CD95 in 
HepG2 cells treated with c-jun siRNA (Figure 16). An upregulation of CD95 on the 
transcription level does not necessarily increase the translational level; therefore protein 
isolation was performed to confirm this result. 
 
 
 
 
 
 
 
Figure 15: c-jun inhibits CD95 signalling pathway upstream of caspase-8  
HepG2 cells were co- transfected with either ctrl-, jun- or casp8 siRNA and were stimulated 30 hours after 
siRNA transfection with indicated dose of LZCD95L. Western blot analysis was performed. β-Actin was used 
as a loading control. 
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A total protein isolation followed by western blot analysis, however showed only a minimal 
change in the level of CD95 protein expression after c-jun- downregulation by siRNA 
transfection. The densitometry analysis showed an increase of approximately two times of 
CD95 receptor protein in c-jun downregulated HepG2 cells (Figure 17).  
Since CD95 receptor is a transmembrane protein, total protein isolation is insufficient to 
detect active CD95 receptor protein located at the cell membrane. C-jun downregulation could 
affect not only the translation level of CD95, but also rapid transport of presynthesized CD95 
receptor molecules stored in vesicles. Therefore, downregulation of c-jun may contribute to 
the upregulation of CD95 cell surface expression.  
 
 
 
 
 
Figure 16: HepG2 cells treated with c-jun siRNA showed an upregulation of CD95 mRNA 
level 
HepG2 cells were transfected with either ctrl- or jun siRNA. After transfection, cDNA was isolated  
and realtime PCR analysis were performed against CD95 receptor. 
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Therefore, we isolated membrane proteins and analyzed the expression of CD95 in the 
membrane and cytosolic fraction using Western blot analysis. 
The results of membrane protein purification in Figure 18 confirmed earlier observations. In 
c-jun downregulated HepG2 cells the level of CD95 receptor was increased compared to 
control siRNA tranfected cells.  
As a loading control of membrane proteins we used E- Cadherin, a transmembrane 
glycoprotein that mediates epithelial cell-to-cell adhesion. The loading control of cytosolic 
proteins was accomplished with GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) 
(Figure 18). 
 
 
 
 
 
 
Figure 17: c-jun- downregulation by siRNA transfection shows a minimal change in the level of CD95 
expression in total cell lysates. 
HepG2 cells were transfected with either ctrl- or jun siRNA and were stimulated 30 hours after siRNA 
transfection with indicated dose of LZCD95L. Western blot analysis was performed at indicated time points. 
Optical density was calculated as follows: For c-jun Western blot (first lane) od1=ctrl siRNA+c-jun band 
density =A; od2=ctrl siRNA+Actin band density = B; A/B = X; od3= jun siRNA+c-jun band density =C; 
od4=jun siRNA+actin band density = D; C/D = Y; Y/X=0,25.  Same calculation was performed for CD95 
antibody. 
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So far, we could show that a downregulation of c-jun in HepG2 cells sensitizes for death 
receptor mediated apoptosis. These results showed an increase of CD95 receptor both at the 
transcriptional and the translational level in c-jun downregulated HepG2 cells. Further c-jun 
downregulation in HepG2 cells increased the membrane protein level of CD95.  
Other components, which play a crucial role in CD95 receptor mediated apoptosis, may also 
be regulated by c-jun downregulation.  
A number of proteins are recruited to the cytoplasmic domain of CD95 receptor protein. 
These include FADD, which functions primarily as an adaptor protein and is a key component 
of the intracellular signalling cascade, which leads to caspase-8 activation.  
In this section, we investigated the phosphorylation status of FADD in HepG2 cells after c-jun 
downregulation. Indeed, we could show in c-jun knockdown HepG2 cells that the adaptor 
protein FADD is unphosphorylated compared to control cells, indicating that c-jun might 
interfere with apoptosis by modifying the phosphorylation status of FADD (Figure 19). 
 
 
Figure 18: Membrane protein purification showed an increase of CD95 receptor levels in c-jun 
downregulated HepG2 cells 
HepG2 cells were treated with ctrl- and jun siRNA. Western blot analysis of membrane and cytosolic 
fraction of siRNA treated HepG2 cells was performed. E- Cadherin were used as loading control for 
membrane fraction and GAPDH were used as loading control for cytosolic fraction. 
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A number of FADD-interacting kinases have been identified and one kinase that has been 
shown to associate with and phoshorylate FADD in vivo is HIPK3 and its splice variant FIST 
[Curtin and Cotter, 2004]. Therefore we hypothesized that HIPK3 and FIST expression are 
regulated through the transcription factor c-jun.  
Taking together, these results showed an unphosphorylated FADD in HepG2 cells treated 
with jun siRNA. 
 
 
 
 
 
 
 
 
 
 
Figure 19:  HepG2 cells treated with jun siRNA shows an unphosphorylated FADD  
HepG2 cells were transfected with either ctrl- or jun siRNA. Western blot analyses were used to 
identify the phosphorylation status of c-jun downregulated HepG2 cells. FADD were used as 
loading control and c-jun was used to confirm c-jun downregulation. 
 
  62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. Discussion 
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HCC is one of the most common cancers in the world, accounting for 6 percent of all cancers 
worldwide and has the fourth highest mortality rate worldwide [Coleman, 2003]. There are 
multiple factors involved for why some people develop HCC and others do not. The most 
significant known factor is the presence of cirrhosis. Other factors may include genetic 
potential, hormonal influences, advancing age, state of general health and nutrition, lifestyle 
habits (especially alcohol abuse), and exposure to viruses and chemicals.  
Apoptosis has also become the focus of many researchers since it became apparent that 
deregulation of the apoptotic programme is pathophysiologically involved in liver diseases 
[Patel et al., 1998]. Evidence indicates that extrinsic and intrinsic apoptosis pathways are 
downregulated in hepatocellular carcinoma. The CD95 receptor, which is normally expressed 
on hepatocytes, is downregulated in liver tumour cells, resulting in double resistance to cell 
death: cells cannot kill themselves via autocrine suicide and the immune system surveillance 
via attacking T- lymphocytes cannot eliminate newly occurring aberrant cells. In an analysis 
of 22 hepatocellular carcinomas, 9 showed no CD95 expressions and 13 had reduced CD95 
expression [Strand et al., 1996]. CD95 also correlated with differentiation of tumour: highly 
differentiated tumours express more CD95 than less differentiated ones [Ito et al., 1998]. 
Therefore, the re-sensitisation of tumour cells is a promising therapeutic strategy. Indeed, re- 
introduction of CD95 into liver tumours cells showed encouraging results in mice [Shimizu et 
al., 1996]. A different approach is the activation of cell death effector molecules, such as 
caspases. Recently, alpha-(trichloromethyl)-4-pyridineethanol was found to facilitate 
apoptosome formation and induce caspase 3 activation in a panel of tumour cells [Jiang et al., 
2003]. For HCC treatment, either proapoptotic pathways can be activated or overactivated 
antiapoptotic mechanisms, such as FLIP or survivin, may be shut down. Small components 
that reactivate caspases or agents, such as siRNA, for downregulation of overactivated 
antiapoptotic pathways are likely to enter the clinic. Numerous methods allow researchers to 
deliver siRNA to the target cells, including nonviral and viral vectors. 
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Alternatively, upstream modifying signalling pathways such as MAPK may be targeted with 
the outcome of apoptosis inhibition or promotion. 
The present study demonstrates, that downregulation of c-jun via siRNA sensitizes hepatoma 
cells to receptor mediated apoptosis. In this context, FADD phosphorylation seems to be 
critical. In addition, c-jun downregulation lead to upregulation of CD95 cell surface protein. 
Therefore, c-jun is a potent target to treat cancer. 
 
1. c-jun is a potent candidate for apoptosis induction in HepG2 cells 
 
As the MAPK signalling pathway not only promotes cell proliferation, but also mediates cell 
survival and is upregulated in cancer cells, it seems to be a good therapeutic target. Especially 
the JNK pathway has been implicated in apoptotic responses to DNA damage, cell stress and 
cytotoxic drugs. It appears that c-Jun N- terminal kinase (JNK) activation is a proapoptotic 
event in non- malignant cells that results in the activation of proapoptotic members of the Bcl-
2 family and cytochrome c release from mitochondria [Nijhawan et al., 2000]. In cells with 
dysregulated proliferation or cell cycle, the role of JNK and c-jun is more controversial. In 
certain cell types, c-jun overexpression is clearly the basis for resistance to DNA-damaging 
drugs, and reversal of resistance has been observed using c-jun antisense RNA. In contrast, 
the proposed role of c-jun as a mediator of apoptosis is further supported by recent data 
describing the regulation and function of components of the mitogen- activated protein kinase 
(MAPK) cascade regulating AP-1 activity. Two types of MAPK, JNK and p38, as well as 
common upstream kinases, including MEKK, are activated by genotoxic agents, such as UV 
and the alkylating agent such as methyl methanesulfonate (MMS), to phosphorylate and 
thereby activate the transcription factor c-jun [Ip and Davis, 1998;Minden and Karin, 1997]. 
Persistent activation of JNK by dominant active MEKK-1 resulted in hyperphosphorylation 
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and activation of c-jun and increased apoptosis in PC12 cells [Le Niculescu et al., 1999]. Vice 
versa, inhibition of JNK activity by transdominant negative mutant conferred resistance to 
apoptosis by various genotoxic agents [Zanke et al., 1996]. In mice lacking the neuron 
specific JNK isoform, JNK3, stimulation of the glutamate receptors does not result  in 
excitotoxicity and apoptosis of hippocampal neurons [Yang et al., 1997b]. In line with this 
data, neuronal apoptosis induced by the excitatory amino acid kainate is absent in mice 
expressing a mutant form of c-jun, which contains amino acid substitutions at the critical JNK 
phosphorylation site [Behrens et al., 1999]. 
Despite these different lines of evidence, suggesting an important role of AP-1 proteins in cell 
death, a direct link between AP-1 activity and the induction of specific initiators or executors 
of apoptosis has not yet been identified. 
To investigate the role of c-jun in hepatocellular carcinoma cell line (HepG2), c-jun was 
downregulated by siRNA. Light microscopic analyses revealed the formation of apoptotic 
bodies. Usually, shedding of apoptotic fragments was accompanied by a condensation of the 
cell. A flow cytometry measurement of cell size and granularity clearly demonstrated that 
downregulation of c-jun in HepG2 cells lead to cell shrinkage and increase granularity. 
These results confirmed earlier studies done in liver cells: Mouse embryos lacking c-jun, due 
to homologous recombination/knock out, died at midgestation and exhibited defects in 
hepatogenesis. There was a dramatic increase in apoptosis in fetal liver in the absence of c-jun 
[Eferl et al., 1999]. Therefore, fetal hepatocytes require c-jun for cell survival. Hepatocellular 
cancer cells like HepG2 behave like fetal liver cells. They also require c-jun for cell survival, 
since c-jun downregulation via siRNA in HepG2 cells leads to apoptosis shown in Figure 2A. 
Differentiated hepatocytes, however, require c-jun for cell cycle progression, since 
conditional deletion of c-jun in adult livers mainly reduced the proliferation capacity of 
hepatocytes after partial hepatectomy, a strong inducer of cell- cycle reentry [Behrens et al., 
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2002]. These liver specific functions of c-jun for cell survival and cell- cycle progression 
imply that this gene is a major regulator in the development of hepatic carcinomas. 
 
2. c-jun inhibition sensitizes HepG2 cells to receptor induced apoptosis 
(Targeting death receptors) 
 
The hepatoma cell line HepG2 was used to study the function of c-jun in death receptor 
mediated apoptosis at a molecular level. The JNK pathway has been shown to be closely 
linked to apoptosis [Davis, 2000]. Studies in this area have also shown, that the MEKK-1/ 
JNK kinase/ JNK/ c-jun axis acts proapoptotically upstream of the CD95 pathway to mediate 
chemotherapeutic drug-induced apoptosis [Eichhorst et al., 2000]. Similarly, deletion of 
single components of the JNK pathway also results in apoptosis and c-jun knockout mice as 
well as MAPK kinase 4 knockout mice die of increased apoptosis in the liver [Yang et al., 
1997a]. The role of c-jun in CD95- mediated apoptosis is less clear. A link between JNK axis 
and the CD95 pathway is provided by the finding that c-jun exerts AP-1-mediated suppression 
of CD95 promoter [Eferl et al., 2003;Ivanov et al., 2002]. Downregulation of CD95 is 
frequently observed during tumour progression. Ivanov et al. demonstrated that ectopic 
expression of dominant- negative mutant of c-jun (TAM67) led to increased CD95 promotor 
activity of CD95 mRNA level in melanoma cells. They also showed that c-jun -/- fibroblasts 
exhibit an increase in CD95 expression in these cells [Ivanov et al., 2003;Ivanov et al., 2002].          
Similarly, we observed the same in HepG2 cells. C-jun downregulation via siRNA led to an 
increase of CD95 receptor expression, both at the transcriptional and translational level. 
Preliminary results showed an increased level of CD95 receptor after downregulation of JNK. 
Our study is the first one to show that c-jun downregulation, the member of AP-1 
transcription factor, increases CD95 expression level in HepG2 cells. One possible 
explanation is the fact, that the CD95 promotor contains three AP-1-binding elements [Ivanov 
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et al., 2003] and binding of AP-1 results in CD95 suppression. Mutations within the promotor 
that abrogate the binding of c-jun are sufficient to increase the CD95 expression. Therefore, 
we conclude, an increase of CD95 expression lead to apoptosis. Through a concomitant 
treatment with death receptor specific ligand, the leucine zipper-tagged CD95 ligand 
(LZCD95L), the apoptosis rate was dramatically increased.  
In the case of the TRAIL-R1 (DR4) and TNFR we saw the same effect. Downregulation of c-
jun and a concomitant application of its specific ligand in HepG2 cells increased the apoptosis 
rate up to 70 % compared to ctrl siRNA transfected cells. Interestingly, the TRAIL-R1 
promotor also contains three putative AP- 1 binding sites. However, Guan et al. showed that 
the human death receptor 4 is upregulated by AP- 1 [Guan et al., 2002]. They showed that 
only one binding site is active and activation of AP- 1 induces a rapid TRAIL-R1 expression 
through binding to the TPA- response element, resulting in apoptosis in H1792 human lung 
adenocarcinoma cells and PC-3 human prostate cancer cells. But c-jun has various functions 
in different tissues. Therefore, downregulation of c-jun via siRNA in HepG2 cells could 
increase the TRAIL-R1 level and a concomitant application of TRAIL results in an increased 
apoptosis rate. Indeed our experiments showed that downregulation of c-jun and concomitant 
application of TRAIL causes increased apoptosis in HepG2 cells. Westernblot analyses could 
show, if downregulation of c-jun increases the expression level of TRAIL-R1. 
Of critical importance during apoptosis through death receptors, is the activation of caspases, 
which are common in both (CD95 and TRAIL) pathways. In this setting, Fas-associating 
protein with death domain (FADD) is a central adaptor molecule to recruit and activate the 
initiator caspase-8 upon ligand-mediated aggregation. 
The caspase-8 is the first caspase, which is activated after activation of the receptor. Parallel 
to the increase of apoptosis as measured by flow cytometry, in c-jun downregulated cells, we 
saw an increase of caspase-8 activation as judged by appearance of its cleaved active subunits 
in the immunoblot. This experiment shows again, that c-jun affects directly the death receptor 
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pathway. Moreover, a co-transfection of casp8 siRNA abolished the effect of c-jun 
downregulation after receptor stimulation, suggesting that c-jun acted upstream of caspase 8, 
likely at the level of CD95 or DISC. 
Recently, researchers could shown, that the phosphorylation of FADD at serine 194 (S191, 
murine FADD) in different tissues is important for regulating apoptosis [Shimada et al., 
2004;Scaffidi et al., 2000;Curtin and Cotter, 2004;Alappat et al., 2005]. 
In this context, we showed that FADD phosphorylation was dependent on c-jun activity in 
hepatoma cells, and inhibition of c-jun using RNAi prevented FADD phosphorylation. 
Recently, Curtin and Cotter identified the kinase HIPK3 and its splice variant FIST the kinase 
that is responsible for the phosphorylation of FADD in prostate carcinoma cells [Curtin and 
Cotter, 2004]. We speculate in our system this kinase could also be important for FADD 
phosphorylation. Further experiments could give some anwers. 
Interestingly, no significant difference was observed in apoptosis rates between ctrl- and jun 
siRNA transfected cells, after concomitant stimulation with TNFα. TNFα signalling shares 
many features with CD95 signalling in the liver, specifically the activation of caspase-8 
including FADD, Bid cleavage and mitochondrial signalling to apoptosis. Oligomerized 
TNFR1 internalizes and via the adaptor protein FADD activates caspase-8 [Hsu et al., 1995]. 
Additionally, other signals emanate from TNFR activation. Activated death receptors recruit 
adaptor proteins, such as tumour necrosis factor receptor associated protein 2 (TRAF2) and 
receptor interacting protein (RIP), that stimulate IκB kinase (IKK) and proteosomal IκB 
degradation, leading to activation and nuclear translocation of NFκB [Barnhart and Peter, 
2003]. NFκB induces increased expression of survival genes, including BclXL, A1, XIAP, 
cFLIP and iNOS [Yin and Ding, 2003;Hatano et al., 2001]. Thus, mouse hepatocytes in 
culture do not undergo apoptosis after exposure to TNFα unless NFκB-dependent gene 
expression is blocked, for example with cycloheximide or introduction of an IκB 
superrepressor [Hatano et al., 2000;Ni et al., 1994]. The ability of TNFα to stimulate both, 
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pro- and antiapoptotic pathways, at least accounts in part for its pleiomorphic and seemingly 
opposing effects. Some reports suggest NFκB-dependent pathways inhibit cell death by 
inactivating JNK pathways, and JNK inhibition attenuates liver injury with preservation of 
hepatic architecture following warm ischemia/reperfusion and cold storage/reperfusion injury 
[Uehara et al., 2005;Uehara et al., 2004]. In our study, c-jun seems to be independent of TNFα 
induced apoptosis. 
In conclusion, we found that the inhibition of c-jun expression in hepatoma cell line HepG2 
reduced FADD phosphorylation and therefore increases the sensitivity of these cells to CD95 
receptor-mediated apoptosis. 
Furthermore, an increase of CD95 receptor both transcriptional and translational level in c-jun 
downregulated HepG2 cells was shown. Therefore, the sensitivity in c-jun downregulated 
HepG2 cells could be due to upregulation of CD95 and also through the reduced FADD 
phosphorylation.  
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3. c-jun and p53 
 
It is tempting to speculate about the relationship between AP-1 and the tumour suppressor 
protein p53 in the context of apoptosis. Both AP-1 and p53 are nuclear transcription factors, 
both are regulated post-transcriptionally by stress signalling pathways, both can induce 
apoptosis in response to genotoxic agents, and both activate extrinsic and mitochondrial death 
pathway components. Furthermore, JNK can phosphorylate p53 and induces protein 
stabilisation. Several recent publications have linked AP- 1 to modulation of the p53 pathway 
to explain the role of AP-1 in cell survival. 
C-jun was described to suppress the transcription of the p53 gene in fibroblasts, which is also 
a known regulator of CD95 expression [Schreiber et al., 1999;Schreiber et al., 1999]. Mouse 
fibroblasts lacking c-jun exhibit upregulated p53 mRNA and protein levels, leading to 
decreased proliferation [Shaulian et al., 2000]. A recent study has provided compelling 
evidence that the oncogenic properties of c-jun may be linked to the antagonism of the pro-
apoptotic activity of the p53 gene. Liver-specific inactivation of the c-jun gene demonstrated 
an essential role in the development of chemically induced hepatocellular carcinomas (HCC) 
[Eferl et al., 2003]. Tumours that developed in the absence of hepatic c-jun expression had 
increased levels of apoptosis. And c-jun null hepatocytes were sensitized to TNFα- induced 
apoptosis. The absence of c-jun in HCC tumours was linked to elevated levels of p53 and its 
pro-apoptotic target gene, Noxa (without effecting other pro- apoptotic p53 targets) [Eferl et 
al., 2003]. In agreement with these observations, we recently found upregulation of p53 and 
CD95 upon treatment HepG2 cells with the JNK inhibitor SP600125 [Kuntzen et al., 2005]. 
In contrast to this data, we could not see an upregualtion of p53 protein in c-jun 
downregulated HepG2 cells. However, experiments in the Huh7 cell line [Nakabayashi et al., 
1982] showed an increase of apoptosis rate both in unstimulated and concomitant death 
receptor stimulated cells. But compared to HepG2 cells the apoptosis rates were generally 
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lower. Presumably p53 is required in liver cells to increase the apoptosis rate. Therefore, we 
conclude that c-jun downregulation sensitizes hepatoma cells to death receptor induced 
apoptosis. p53 is needed to further increase the apoptosis rate. 
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V. Summary 
 
C-jun is a proto-oncogene and member of the AP-1 transcription factor family. Although c-
jun was shown to be involved in many different cellular functions including cell proliferation, 
differentiation, transformation and apoptosis in different cell types, its role in carcinogenesis 
remains elusive.  
In this report we investigated the hypothesis that c-jun played a role in liver tumourigenesis 
by inhibiting the CD95 signaling pathways. To this aim, we investigated apoptosis rates in 
HepG2 and Huh7 hepatoma cells after inhibition of c-jun and concomitant incubation with 
several apoptosis-inducing substances.  
We showed an effective suppression of c-jun both at the RNA and protein level after 
transfection with siRNA directed against c-jun. Functional suppression was confirmed by 
Luciferase- reportergen assays. Flow cytometry analysis showed a significant increase in the 
apoptosis rate in c-jun downregulated HepG2 cells. Moreover, incubation of HepG2 with the 
death receptor ligands CD95L and TRAIL and the chemotherapeutic agent 5- FU causes up to 
60% apoptosis compared to control siRNA treated cells. This effect was not observed in cells 
treated with TNF-α. In contrast to HepG2 cells, experiments in Huh7 cells also showed an 
increase of the apoptosis rate in c-jun downregulated cells, but compared to HepG2 cells, the 
apoptosis rates were generally lower. Presumably, the mutated p53 gene played a role in 
Huh7 cells. Moreover, in correlation with c-jun downregulation an increase of the non-
phosphorylated active form of FADD, which mediated caspase activation downstream of 
CD95 and TRAIL receptors, could be observed 
Therefore we conclude c-jun downregulation inhibits the FADD phosphorylation and causes 
the sensitization of HepG2 cells to CD95L, TRAIL and 5-FU-mediated apoptosis. 
Pharmacologic inhibition of c-jun may therefore serve as effective cancer therapy. 
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VI. Zusammenfassung 
 
c-jun ist ein Mitglied der AP–1 Transkriptionsfaktorfamilie und wurde als Protoonkogen 
beschrieben. Bisherige Arbeiten konnten zeigen, das c-jun in vielen verschiedenen zellulären 
Funktionen wie Proliferation, Differenzierung, Transformation und Apoptose involviert ist. 
Die Funktion von c-jun ist abhängig von der zellulären Differenzierung und vom Zelltyp. Der 
Mechanismus jedoch, über den c-jun zur Karzinognese beiträgt, ist noch zu klären. 
In dieser Arbeit haben wir die Rolle von c-jun in der Karzinogenes und seine Rolle in Bezug 
auf Apoptose über den CD95 vermittelten Signalweg untersucht. Dazu wurde die 
Apoptoserate in den Hepatomzelllinien HepG2 und HUH7 nach Inhibierung von c-jun und 
nachträglicher Inkubation mit verschiedenen Apoptose auslösenden Substanzen, gemessen.  
Wir konnten zeigen, dass eine siRNA-Transfektion zur erfolgreichen Herabregulation des c-
Jun Transkriptionsfaktors sowohl auf RNA- als auch auf Proteinebene, führt. Dieser Effekt 
konnte, wie eine kinetische Analyse zeigte, über fünf Tage beobachtet werden. Die 
funktionale Suppression von c-jun konnte mit Hilfe eines Luciferase-Reportergenassays 
bestätigt werden. Durchflusszytometrische Analysen zeigten eine signifikante Erhöhung der 
Apoptoserate nach siRNA-Transfektion. Darüber hinaus führte eine Herunterregulation von c-
jun und eine anschließende Stimulation mit CD95L und TRAIL sowie mit dem 
Chemotherapeutikum 5-FU, verglichen mit Kontrollen, zu einer weiteren Steigerung der 
Apoptoserate auf bis zu 60%. Weiterhin konnte gezeigt werden, dass eine Stimulation mit 
dem Tumournekrosefaktor alpha (TNF-α) nach c-jun Herunterregulierung keine signifikanten 
Unterschied zwischen den Kontrollzellen aufwies. Ähnliche Ergebnisse wurden in Huh7 
Zellen beobachtet, die experimentell gleich behandelt wurden. Jedoch zeigte sich hier, dass 
die Apoptoserate insgesamt niedriger war als in HepG2 Zellen. Mögliche Erklärung könnte 
das p53 Gen sein, welches in diesen Zellen in mutierter Form vorliegt. Weiterhin konnte 
gezeigt werden, dass in c-jun herunterregulierten Zellen die nicht phoshorylierte Form von 
FADD vorlag, welches die caspase Aktivierung downstream von CD95 and TRAIL 
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Rezeptoren vermittelt. Somit kann Zusammengefasst werden, dass eine Herabregulierung von 
c-jun eine Inhibierung der FADD Phosphorylierung zu Folge hat und dieses dazu führt, dass 
HepG2 Zellen auf CD95L, TRAIL and 5-FU vermittelte Apoptose sensitiviert werden.  
Eine pharmakologische Inhibierung des c-jun in diesen Zellen, könnte somit als ein wichtiger 
Faktor in der Krebstherapie eingesetzt werden. 
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